Devonian获加拿大卫生部批准，启动Thykamine小儿特应性皮炎II/III期试验

环球市场播报07-21

Devonian Health Group（TSXV：GSD）7月21日宣布，已获得加拿大卫生部的临床试验申请授权，将启动PUR 0110（Thykamine™）乳膏治疗小儿轻中度特应性皮炎的II/III期临床研究。　　此次授权允许研究覆盖从3个月婴儿到17岁青少年的全部儿科人群，是Devonian的一个关键监管里程碑。该试验将由加拿大多伦多大学皮肤科临床副教授、国际知名皮肤科专家Charles...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2653187205?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-21 22:21","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2653187205","market":"hk","top_or_hot":-1,"title":"Devonian获加拿大卫生部批准，启动Thykamine小儿特应性皮炎II/III期试验","media":"环球市场播报","content":"<div>\n<p>Devonian Health Group（TSXV：GSD）7月21日宣布，已获得加拿大卫生部的临床试验申请授权，将启动PUR 0110（Thykamine™）乳膏治疗小儿轻中度特应性皮炎的II/III期临床研究。\n　　此次授权允许研究覆盖从3个月婴儿到17岁青少年的全部儿科人群，是Devonian的一个关键监管里程碑。该试验将由加拿大多伦多大学皮肤科临床副教授、国际知名皮肤科专家Charles...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-21/doc-iniiqvau9122982.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Devonian获加拿大卫生部批准，启动Thykamine小儿特应性皮炎II/III期试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDevonian获加拿大卫生部批准，启动Thykamine小儿特应性皮炎II/III期试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-21 22:21 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-07-21/doc-iniiqvau9122982.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Devonian Health Group（TSXV：GSD）7月21日宣布，已获得加拿大卫生部的临床试验申请授权，将启动PUR 0110（Thykamine™）乳膏治疗小儿轻中度特应性皮炎的II/III期临床研究。\n　　此次授权允许研究覆盖从3个月婴儿到17岁青少年的全部儿科人群，是Devonian的一个关键监管里程碑。该试验将由加拿大多伦多大学皮肤科临床副教授、国际知名皮肤科专家Charles...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-21/doc-iniiqvau9122982.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-21/doc-iniiqvau9122982.shtml","article_id":"2653187205","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653187205","pubTimestamp":1784643660,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"Devonian Health Group7月21日宣布，已获得加拿大卫生部的临床试验申请授权，将启动PUR 0110乳膏治疗小儿轻中度特应性皮炎的II/III期临床研究。此次儿科项目基于此前成人II期试验取得的积极结果，该结果已发表于同行评议期刊《Journal of Drugs in Dermatology》，显示Thykamine乳膏在成人轻中度特应性皮炎中具有统计学显著的疗效和良好的安全性。特应性皮炎是全球最常见的儿童慢性炎症皮肤病之一，约60%患儿在一岁内发病，85%在五岁前患病。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4134":"信息科技咨询与其它服务","III":"信息服务"},"translate_title":"Devonian receives Health Canada approval to initiate Phase II/III trial of Thykamine in pediatric atopic dermatitis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5},"content_text":"Devonian Health Group（TSXV：GSD）7月21日宣布，已获得加拿大卫生部的临床试验申请授权，将启动PUR 0110（Thykamine™）乳膏治疗小儿轻中度特应性皮炎的II/III期临床研究。\n　　此次授权允许研究覆盖从3个月婴儿到17岁青少年的全部儿科人群，是Devonian的一个关键监管里程碑。该试验将由加拿大多伦多大学皮肤科临床副教授、国际知名皮肤科专家Charles Lynde博士牵头，通过多个顶级儿科皮肤科中心开展。\n　　该试验采用无缝适应性II/III期设计，计划招募约306名小儿患者：II期102名、III期增加204名，均衡分配至0.05%和0.1%两种浓度的Thykamine乳膏组或安慰剂组。主要疗效终点为治疗12周后达到vIGA-AD评分“清除”或“几乎清除”且较基线改善至少两个等级的患者比例。研究设独立数据安全监测委员会，采用两年龄段序贯入组（2-17岁69名，3个月至2岁33名）并设有明确停止规则，以保障安全。\n　　Devonian首席执行官André P． Boulet表示，该授权体现了公司科学和监管策略的实力，也反映了儿童特应性皮炎安全有效疗法的迫切需求。此次儿科项目基于此前成人II期试验取得的积极结果，该结果已发表于同行评议期刊《Journal of Drugs in Dermatology》，显示Thykamine乳膏在成人轻中度特应性皮炎中具有统计学显著的疗效和良好的安全性。特应性皮炎是全球最常见的儿童慢性炎症皮肤病之一，约60%患儿在一岁内发病，85%在五岁前患病。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653187205","isCrawlerRequest":true}